FLT3 and acute myeloid leukemia: The HOVON 156 AML trial is another phase III trial currently in the last stages, having accrued 738 of the 768 needed and is currently on a brief HOLD and will shed light on the efficacy of upfront gilteritinib another FLT3 inhibitor that is being compared to midostaurin when added to 7 + 3 induction chemotherapy.